2019 Report On Big Health Corporate Social Responsibility Report: Seven Indicators To Quantify How Nearly 300 Pharmaceutical Listed Companies Reshape Corporate Social Responsibility In The Throes Of Transformation

Twenty-first Century researcher Tang Weike, Zhu Ping, Lu Shan, Chen Hongxia

In twenty-first Century, the new health team of the economic report, as an industry observer, has been committed to promoting sustainable development of the industry. For large health enterprises, they are responsible for protecting national health, which is more important than other industries' social responsibilities.

In the past 2019, China's big health industry has come to a crossroads: it is a year when policy has strongly affected the industry, and it is also a painful year for industry transformation.

In 2019, frequent incidents of black swans in the big health industry, the inflated monetary fund, the killing of wives by the chairman, the massive bribery of children to school, and the bankruptcy of the problem vaccine enterprises were frequent.

At the level of industry policy, the expansion of drug quantity, purchase and purchase of medical insurance, cataloging and negotiation of medical insurance, the consistency evaluation of generic drugs, the monitoring of auxiliary drugs, the strictness of drug control and control fees, the reform of medical insurance payment, the control of drug proportion and other heavy medical insurance information systems, the overhaul of the drug administration law, the implementation plan of "healthy China action - cancer prevention and treatment plan (2019 to 2022)" and other heavy policies have been introduced, all of which reshaped the industry pattern from different angles.

Against this background, in twenty-first Century, the new health acquisition team of the economic report in twenty-first Century selected 300 health care listed companies from around the world to quantify the performance of CSR for each company by using the first established quantitative evaluation system of CSR for medical and health enterprises, and finally launched the "2019 China health care listed company social responsibility report" (hereinafter referred to as the "report").

Seven indicators, nearly 300 enterprises quantitative score

Continue to observe the path to Chinese pharmaceutical enterprises. In twenty-first Century 2019, the economic report industrial research institute once again carried out health scanning for 291 listed companies in the big health industry.

The evaluation standard includes 7 indicators: economic efficiency, environmental protection, product quality and safety, fair competition, employee remuneration, social welfare and social responsibility report. According to the importance of these seven dimensions, different proportions should be set up so as to directly and comprehensively understand the fulfillment of CSR of enterprises.

1. economic efficiency (10 points). One of the most important indicators for enterprises is economic efficiency. The net profit rate is used to judge the economic efficiency of enterprises.

2. environmental protection (20 points). As the main body of pollution prevention, enterprises must fulfill their environmental responsibilities according to law.

3. product quality safety (20 points). As a medical enterprise, the first priority is drug safety. The quality and safety problems of medical enterprises in 2018 were graded according to the severity and frequency of quality problems.

4. fair competition (10 points). Fair competition among enterprises can promote the sound and rapid development of the medical industry.

5. employee pay (10 points). Employee pay is one of the most important criteria for measuring a company's welfare system and corporate culture.

6. social welfare (10 points). Social welfare is also an indispensable part of an enterprise.

7. social responsibility report (20 points). Corporate social responsibility report is an important position to show enterprises' activities and public welfare projects during the reporting period.

The total score of the seven indicators is 100 points, which reflects the overall situation of corporate social responsibility from different angles.

Product quality and safety, social responsibility report can get a full score of 20 points, only 1. For employees, only 3 out of 8 and above.

Of the 291 enterprises, the highest score was 85.1, the lowest score was 24.9, the total average score was 56.8, and failed. There were only 8 out of 80 and above, accounting for 2.7%; 60 and more than 109, accounting for 37.4%. This shows that the performance of CSR of Chinese health care enterprises in 2019 is not optimistic.

On the whole, the top 20 enterprises are: pharmacology, Huarun 39, Hong Hong pharmaceutical, Fuxing medicine, MINDRAY medical treatment, Jiang Zhong pharmaceutical, AI Er Ophthalmology, Tiantan biology, Qi Zheng Tibetan medicine, kirun medicine, Xin He Cheng, Guizhou bailing, Ji Chuan pharmaceutical, Ya Bao medicine, Hai Hai Lai, Tong Hua Dong Bao, national medicine is consistent, Hai Zheng pharmaceutical, sunflower medicine, double Heron medicine.

Labor transformation, reshaping corporate social responsibility

In recent years, the medical industry is the "main battlefield" where capital continues to be active. In 2018, the total value of China's pharmaceutical market reached US $130 billion, the second largest pharmaceutical market in the world after the United States. According to IQVIA data, in 2018, the total sales volume of China's hospital drug market reached 771 billion 800 million yuan, an annual growth rate of 3.3%. The annual sales of multinational pharmaceutical companies and local pharmaceutical enterprises were 208 billion 400 million and 563 billion 400 million yuan respectively.

But at the same time, like many industries, China's pharmaceutical industry has reached a new crossroads. 2019 is a year of great changes in China's health industry. It is a year when the policy falls to the radiation industry. It is also a year of painful transformation in the industry.

No ability to participate in the volume of procurement enterprises, no funds to do generic drug consistency evaluation of enterprises, lack of money and lack of ability to do innovative transformation of enterprises, get together to do the same kind of "innovative medicine" enterprises, control fees policy leading to the main business profitability decline in enterprises, compliance management, lack of operation capacity of enterprises...... In this round of transformation tide will face "cold winter".

Under the "cold winter", the fulfillment of social responsibility of large and healthy enterprises is not optimistic.

According to the data of the State Administration of drug control, in 2018, regulators at all levels accepted 64 thousand drug complaints and filed 3556 cases, and 4036 cases were closed. 18 thousand complaints and reports on medical devices were accepted, 1026 cases were filed and 1087 cases were closed. A total of 98 thousand drug cases were investigated, the value of goods was 2 billion 740 million yuan, the fine was 7 billion 660 million yuan, the amount of illegal income was confiscated by 2 billion yuan, the number of unlicensed businesses was banned, 1037 households were destroyed, 148 counterfeiting and selling dens were destroyed, 1093 households were shut down and shut down, 197 licenses were revoked and 2000 were transferred to judicial organs.

A total of 249 cases of drug packaging materials were investigated and the value of goods was 1 million 264 thousand yuan. 18 thousand cases of medical device cases, the value of goods 210 million yuan, a fine of 570 million yuan, confiscation of illegal income of 17 million 267 thousand yuan, the suppression of unlicensed business 188 households, smashed counterfeit and selling dens 6, ordered to suspend production and shut down 89 households, revoke the license 7, transferred to judicial organs 41.

There is no doubt that social responsibility is still a long way to go for medical listed companies. Whether we can handle the existing problems in a fixed, insisting and candid way, and report to the public at the same time each year, is also an important topic to measure whether a company can develop healthily.

Looking forward to the future, corporate social responsibility is a long way to go.

The implementation of social responsibility of medical enterprises is a long way to go.

From the overall score of the report, the highest score is 85.1, the lowest score is 24.9, the total average score is 56.8, and no pass line has been reached. There were only 8 out of 80 and above, accounting for 2.7%; 60 and more than 109, accounting for 37.4%. This shows that the performance of social responsibility of China's big health enterprises in 2019 is not optimistic.

From the point of view of plates, medical and health enterprises are mainly divided into three parts: biopharmaceuticals, medical consumables and medical services. In this score, there are 195 Biopharmaceutical Enterprises, 55 medical device consumables enterprises, and 38 medical service enterprises. Its various aspects are as follows:

In terms of social responsibility reports, biopharmaceutical sector enterprises accounted for 117 enterprises with less than 10 points, accounting for 60% of the statistics; 36 of the medical device consumables enterprises were below 10, accounting for 65% of the statistics; 21 of the 10 medical service departments accounted for 55% of the total statistics.

In terms of social welfare, a total of 59 enterprises in biopharmaceutical sector accounted for zero in the social aspect, accounting for 37% of the statistical data; 23 of the medical device consumables sector got zero, accounting for 42% of the statistics; 11 of the medical services got zero, accounting for 29% of the statistics.

In terms of environmental protection, biopharmaceutical sector enterprises have a total of 63 enterprises below 10 points, accounting for 40% of the statistics; 34 of the medical device consumables enterprises are below 10, accounting for 62% of the statistics; 25 of the medical service enterprises are below 10, accounting for 66% of the statistics.

In terms of accepting administrative penalties or serious violations, 195 Biopharmaceutical Enterprises received more than 110 administrative penalties or serious violations, accounting for 56% of the total statistics; 28 of the medical device consumables enterprises received administrative penalties or serious violations, accounting for 51% of the statistics; 20 of the medical service enterprises received administrative penalties or serious violations, accounting for 53% of the statistics.

From the above data, China's biopharmaceuticals, medical equipment consumables, medical services and other enterprises in social responsibility, social welfare, environmental protection and other aspects need to be strengthened.

The fulfillment of social responsibility of pharmaceutical enterprises has gradually become an important part of enterprise brand and a significant symbol of core competitiveness. The international community attaches great importance to corporate social responsibility. China's pharmaceutical enterprises should move towards the international community and move forward from a big pharmaceutical country to a pharmaceutical power, and the social responsibility system must meet international standards. In addition, because the production behavior of pharmaceutical enterprises is related to public health, the connotation of corporate responsibility is more abundant than that of ordinary types of enterprises.

At present, China's medical and health industry is taking an increasingly open and integrated attitude to set off a wave of change in rules reconstruction and structural adjustment. The integration of industries and large mergers and acquisitions will accelerate the role of capital and promote further transformation and upgrading of industries. In the way of reshaping the industry, risks and opportunities coexist. It is a compulsory course for enterprises to grasp the policy trend and make timely adjustment.

Under the requirements of high barriers, high risks, high quality and strict supervision, enterprises should make higher demands on themselves in terms of social responsibility: to have more responsibility for enterprises, society, employees and the public, so as to maintain the long-term development of enterprises and jointly promote the healthy development of the industry.